New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse

De Luca A, Pierno S, Liantonio A, Desaphy JF, Natuzzi F, Didonna MP, Ferrannini E, Jockusch H, Franchini C, Lentini G, Corbo F, et al. (2004)
NEUROMUSCULAR DISORDERS 14(7): 405-416.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
The antimyotonic activity of chiral derivatives of mexiletine and tocainide, selected as potent use-dependent blockers of skeletal muscle sodium channels, was evaluated in vivo acutely in myotonic ADR mice. The compounds had either aromatic (Me4 and Me6) or branched isopropyl groups (Me5 and To1) on the asymmetric centre, or had this latter one methylene apart from the amino group (Me2). Therapeutic doses of mexiletine (5-10 mg/kg) and tocainide (7-20 mg/kg) significantly reduced the long time of righting reflex (TRR), typical of ADR mice. Me4, Me5 and Me6 were 2-fold more potent than mexiletine. Tot fully normalised the TRR at 7 mg/kg. The electromyographic analysis confirmed a muscle-based activity for drug effectiveness on TRR. All the compounds reduced the myotonic hyperexcitability of intercostal muscle fibres when tested in vitro by current-clamp recordings, with a potency correlated with their action on sodium channels. On stimulus-evoked firing, the isopropyl analogues were 2-4-fold more potent than parent compounds, while the aromatic analogues were about 10-fold more potent than mexiletine. Patch-clamp recordings confirmed a normal-like pharmacological sensitivity of sodium channels of native ADR muscle fibres. Finally, the in vivo antimyotonic activity is due to the block of sodium channels and divergences with in vitro potency can be related to structure-based changes in drug pharmacokinetics. (C) 2004 Elsevier B.V. All rights reserved.
Erscheinungsjahr
Zeitschriftentitel
NEUROMUSCULAR DISORDERS
Band
14
Ausgabe
7
Seite(n)
405-416
ISSN
PUB-ID

Zitieren

De Luca A, Pierno S, Liantonio A, et al. New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. NEUROMUSCULAR DISORDERS. 2004;14(7):405-416.
De Luca, A., Pierno, S., Liantonio, A., Desaphy, J. F., Natuzzi, F., Didonna, M. P., Ferrannini, E., et al. (2004). New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. NEUROMUSCULAR DISORDERS, 14(7), 405-416. doi:10.1016/j.nmd.2004.04.006
De Luca, A., Pierno, S., Liantonio, A., Desaphy, J. F., Natuzzi, F., Didonna, M. P., Ferrannini, E., Jockusch, H., Franchini, C., Lentini, G., et al. (2004). New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. NEUROMUSCULAR DISORDERS 14, 405-416.
De Luca, A., et al., 2004. New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. NEUROMUSCULAR DISORDERS, 14(7), p 405-416.
A. De Luca, et al., “New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse”, NEUROMUSCULAR DISORDERS, vol. 14, 2004, pp. 405-416.
De Luca, A., Pierno, S., Liantonio, A., Desaphy, J.F., Natuzzi, F., Didonna, M.P., Ferrannini, E., Jockusch, H., Franchini, C., Lentini, G., Corbo, F., Tortorella, V., Camerino, D.C.: New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. NEUROMUSCULAR DISORDERS. 14, 405-416 (2004).
De Luca, A, Pierno, S, Liantonio, A, Desaphy, JF, Natuzzi, F, Didonna, MP, Ferrannini, E, Jockusch, Harald, Franchini, C, Lentini, G, Corbo, F, Tortorella, V, and Camerino, DC. “New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse”. NEUROMUSCULAR DISORDERS 14.7 (2004): 405-416.

13 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Beyond the muscular involvement in non-dystrophic myotonias: The emerging role of neuromodulation.
Portaro S, Naro A, Bramanti A, Leo A, Manuli A, Balletta T, Trinchera A, Bramanti P, Calabrò RS., Restor Neurol Neurosci 36(4), 2018
PMID: 29889082
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.
De Bellis M, Carbonara R, Roussel J, Farinato A, Massari A, Pierno S, Muraglia M, Corbo F, Franchini C, Carratù MR, De Luca A, Conte Camerino D, Desaphy JF., Neuropharmacology 113(pt a), 2017
PMID: 27743929
Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.
De Bellis M, Sanarica F, Carocci A, Lentini G, Pierno S, Rolland JF, Conte Camerino D, De Luca A., Front Pharmacol 8(), 2017
PMID: 29379434
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D., Front Pharmacol 7(), 2016
PMID: 27242528
Sodium channel slow inactivation as a therapeutic target for myotonia congenita.
Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM., Ann Neurol 77(2), 2015
PMID: 25515836
Taurine: the appeal of a safe amino acid for skeletal muscle disorders.
De Luca A, Pierno S, Camerino DC., J Transl Med 13(), 2015
PMID: 26208967
Late Na(+) current and protracted electrical recovery are critical determinants of the aging myopathy.
Signore S, Sorrentino A, Borghetti G, Cannata A, Meo M, Zhou Y, Kannappan R, Pasqualini F, O'Malley H, Sundman M, Tsigkas N, Zhang E, Arranto C, Mangiaracina C, Isobe K, Sena BF, Kim J, Goichberg P, Nahrendorf M, Isom LL, Leri A, Anversa P, Rota M., Nat Commun 6(), 2015
PMID: 26541940
In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.
Desaphy JF, Costanza T, Carbonara R, Conte Camerino D., Neuropharmacology 65(), 2013
PMID: 23000075
Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.
De Bellis M, De Luca A, Desaphy JF, Carbonara R, Heiny JA, Kennedy A, Carocci A, Cavalluzzi MM, Lentini G, Franchini C, Camerino DC., Biophys J 104(2), 2013
PMID: 23442856
Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.
De Luca A, De Bellis M, Corbo F, Franchini C, Muraglia M, Catalano A, Carocci A, Camerino DC., Neuromuscul Disord 22(1), 2012
PMID: 21802953
Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine.
Desaphy JF, Dipalma A, Costanza T, Carbonara R, Dinardo MM, Catalano A, Carocci A, Lentini G, Franchini C, Camerino DC., Front Pharmacol 3(), 2012
PMID: 22403541
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.
Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG, Consortium for Clinical Investigation of Neurologic Channelopathies., JAMA 308(13), 2012
PMID: 23032552
Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.
Carocci A, Catalano A, Bruno C, Lentini G, Franchini C, De Bellis M, De Luca A, Conte Camerino D., Chirality 22(3), 2010
PMID: 19544349

44 References

Daten bereitgestellt von Europe PubMed Central.

Skeletal muscle channelopathies.
Jurkat-Rott K, Lerche H, Lehmann-Horn F., J. Neurol. 249(11), 2002
PMID: 12420087
Periodic paralysis: understanding channelopathies.
Lehmann-Horn F, Jurkat-Rott K, Rudel R., Curr Neurol Neurosci Rep 2(1), 2002
PMID: 11898585

Rüdel, 1994
Molecular structure and physiological function of chloride channels.
Jentsch TJ, Stein V, Weinreich F, Zdebik AA., Physiol. Rev. 82(2), 2002
PMID: 11917096
The familial periodic paralyses and nondystrophic myotonias.
Ptacek L., Am. J. Med. 105(1), 1998
PMID: 9688022
Clinical pharmacokinetics of mexiletine.
Labbe L, Turgeon J., Clin Pharmacokinet 37(5), 1999
PMID: 10589372
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, Cerskus I, Roden D., Am. Heart J. 107(5 Pt 2), 1984
PMID: 6326558
Drug therapy. Tocainide.
Roden DM, Woosley RL., N. Engl. J. Med. 315(1), 1986
PMID: 3086724
Molecular mechanisms of gating and drug block of sodium channels.
Catterall WA., Novartis Found. Symp. 241(), 2002
PMID: 11771647
Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA., Proc. Natl. Acad. Sci. U.S.A. 93(17), 1996
PMID: 8799190
Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.
De Luca A, Natuzzi F, Falcone G, Duranti A, Lentini G, Franchini C, Tortorella V, Camerino DC., Naunyn Schmiedebergs Arch. Pharmacol. 356(6), 1997
PMID: 9453464
Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.
De Luca A, Natuzzi F, Desaphy JF, Loni G, Lentini G, Franchini C, Tortorella V, Camerino DC., Mol. Pharmacol. 57(2), 2000
PMID: 10648636
Inactivation of muscle chloride channel by transposon insertion in myotonic mice.
Steinmeyer K, Klocke R, Ortland C, Gronemeier M, Jockusch H, Grunder S, Jentsch TJ., Nature 354(6351), 1991
PMID: 1659665
Nonsense and missense mutations in the muscular chloride channel gene Clc-1 of myotonic mice.
Gronemeier M, Condie A, Prosser J, Steinmeyer K, Jentsch TJ, Jockusch H., J. Biol. Chem. 269(8), 1994
PMID: 8119941
The myotonic mouse mutant ADR: electrophysiology of the muscle fiber.
Mehrke G, Brinkmeier H, Jockusch H., Muscle Nerve 11(5), 1988
PMID: 2453798
The myotonic mouse mutant ADR: physiological and histochemical properties of muscle.
Reininghaus J, Fuchtbauer EM, Bertram K, Jockusch H., Muscle Nerve 11(5), 1988
PMID: 2967431
Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.
De Luca A, Pierno S, Natuzzi F, Franchini C, Duranti A, Lentini G, Tortorella V, Jockusch H, Camerino DC., J. Pharmacol. Exp. Ther. 282(1), 1997
PMID: 9223544
Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.
Talon S, De Luca A, De Bellis M, Desaphy JF, Lentini G, Scilimati A, Corbo F, Franchini C, Tortorella P, Jockusch H, Conte Camerino D., Br. J. Pharmacol. 134(7), 2001
PMID: 11724759
Antimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goats.
Camerino DC, Pierno S, De Luca A, Bryant SH., Neuromuscul. Disord. 10(3), 2000
PMID: 10734261
Chloride channel regulation in the skeletal muscle of normal and myotonic goats.
Bryant SH, Conte-Camerino D., Pflugers Arch. 417(6), 1991
PMID: 1711670
On the repetitive discharge in myotonic muscle fibres.
Adrian RH, Bryant SH., J. Physiol. (Lond.) 240(2), 1974
PMID: 4420758
The mechanism of action of dantrolene sodium.
Morgan KG, Bryant SH., J. Pharmacol. Exp. Ther. 201(1), 1977
PMID: 321754
Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.
Desaphy JF, Conte Camerino D, Franchini C, Lentini G, Tortorella V, De Luca A., Br. J. Pharmacol. 128(6), 1999
PMID: 10578128
Stereospecific synthesis and absolute configuration of mexiletine
Franchini, Chirality 6(), 1994
Facile entry to (-)-(R)- and (+)-(S)-mexiletine.
Carocci A, Franchini C, Lentini G, Loiodice F, Tortorella V., Chirality 12(3), 2000
PMID: 10689287
Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity.
Franchini C, Corbo F, Lentini G, Bruno G, Scilimati A, Tortorella V, Conte Camerino D, De Luca A., J. Med. Chem. 43(20), 2000
PMID: 11020295

Tallarida, 1979
Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy.
Jackson CE, Barohn RJ, Ptacek LJ., Muscle Nerve 17(7), 1994
PMID: 8008003
Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbe L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J., Clin. Pharmacol. Ther. 68(1), 2000
PMID: 10945315
Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms.
Honma W, Kamiyama Y, Yoshinari K, Sasano H, Shimada M, Nagata K, Yamazoe Y., Drug Metab. Dispos. 29(3), 2001
PMID: 11181495
Effects of mexiletine on ATP sensitive K+ channel of rat skeletal muscle fibres: a state dependent mechanism of action.
Tricarico D, Barbieri M, Franchini C, Tortorella V, Camerino DC., Br. J. Pharmacol. 125(4), 1998
PMID: 9831925
Keeping health and safety first.
Hicks JM., Lab Anim (NY) 29(5), 2000
PMID: 11381217
Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.
De Luca A, Talon S, De Bellis M, Desaphy JF, Franchini C, Lentini G, Catalano A, Corbo F, Tortorella V, Conte-Camerino D., Naunyn Schmiedebergs Arch. Pharmacol. 367(3), 2003
PMID: 12644906
Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia.
Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G., Ann. Neurol. 53(6), 2003
PMID: 12783414
Meta-hydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation.
Grech-Belanger O, Turgeon J, Lalande M, Belanger PM., Drug Metab. Dispos. 19(2), 1991
PMID: 1676654
Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination.
Turgeon J, Pare JR, Lalande M, Grech-Belanger O, Belanger PM., Drug Metab. Dispos. 20(5), 1992
PMID: 1358583
Stereospecific synthesis of "para-hydroxymexiletine" and sodium channel blocking activity evaluation.
Catalano A, Carocci A, Fracchiolla G, Franchini C, Lentini G, Tortorella V, De Luca A, De Bellis M, Desaphy JF, Conte Camerino D., Chirality 16(2), 2004
PMID: 14712469
Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative.
Desaphy JF, De Luca A, Tortorella P, De Vito D, George AL Jr, Conte Camerino D., Neurology 57(10), 2001
PMID: 11723275
Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis.
Weckbecker K, Wurz A, Mohammadi B, Mansuroglu T, George AL Jr, Lerche H, Dengler R, Lehmann-Horn F, Mitrovic N., Neuromuscul. Disord. 10(1), 2000
PMID: 10677861

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 15210163
PubMed | Europe PMC

Suchen in

Google Scholar